- Article
- Source: Campus Sanofi
- 23 Oct 2023
Praluent® (alirocumab) PubExplainer
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/salud-digital_1.jpg0/jcr:content/salud-digital_1.jpg)
![Praluent logo](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Praluent_hero.png/jcr:content/Praluent_hero.png)
Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
†With only nominal statistical significance by hierarchical testing (HR 0.85, 95% CI 0.73, 0.98)
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
Praluent®
Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Dyslipidaemia/unmet-needs/Image/Group-44.jpg/jcr:content/Group%2044.jpg)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Products/admelog/MicrosoftTeams-image--2-.png6/jcr:content/MicrosoftTeams-image%20(2).png)
MAT-XU-2204597 (v3.0) Date of Preparation: October 2023